In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exit, Pursued By a Bear

Executive Summary

The buzz of Phoenix '99: In the teeth of their own bear market, device companies are running for any exit they can find because, until recently, the favored exit strategies for small, private medical device companies have been fairly traditional--going public and/or being acquired by a larger firm. But given the dismal performance of small cap device companies recently, the public markets virtually closed down for product companies, leaving only the M&A route. Dealmaking has become more viable as big companies increasingly look to small ones for new products, while small firms gain access to distribution channels, creating a greater co-dependency between the two. In 1999, however, even the M&A door has slammed shut, leaving small companies looking for new financing and business models to deal with the current lack of exit options.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel